ArticleIBRO neuroscience reports2026
TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLF15-POU3F4 axis activates PI3K/AKT signaling to promote glioma progression.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the mechanisms by which TNKS1 regulates glycolysis and proliferation in glioma. Methods: Cell viability was assessed using the CCK-8 assay. Levels of glucose and lactate were measured using biochemical detection kits. Western blotting was used to detect the expression levels of glycolysis-related proteins, and qPCR was employed to measure the mRNA expression of GLUT1 and HK2. A subcutaneous xenograft tumor model in nude mice was established. After intratumoral injection of drugs, the effects of TNKS1 knockdown on tumor tissues were observed using HE staining and immunohistochemical staining. Western blotting was also used to detect the expression of PTEN and other proteins in glioma tissues. Results: Compared with the control group, TNKS1 knockdown resulted in increased expression of PTEN, decreased expression of PI3K and p-AKT/AKT proteins, reduced cell proliferation capacity, and lower glucose uptake and lactate production. The results were opposite in the TNKS1 overexpression group. In the group treated with a PI3K agonist compared with the untreated group, the expression of PI3K and p-AKT/AKT proteins increased, and cell proliferation capacity, glucose uptake, and lactate production also increased to varying degrees. In the TNKS1 overexpression + PI3K inhibitor group compared with the TNKS1 overexpression group, the expression of PI3K and p-AKT/AKT proteins decreased, and cell proliferation capacity, glucose uptake, and lactate production also decreased to varying degrees. In the in vivo experiments, compared with the control group, the TNKS1 knockdown group showed increased tumor cell apoptosis and necrosis. Immunohistochemical and Western blotting analyses indicated that compared with the TNKS1-siRNA empty vector group, the TNKS1-siRNA group had significantly increased PTEN protein expression. The expression levels of PI3K, p-AKT/AKT proteins, and Ki67 were significantly lower in the TNKS1-siRNA group, inhibitor group, and TNKS1-siRNA + inhibitor group. Conclusion: TNKS1 regulates glycolysis and proliferation in glioma by mediating the PTEN-PI3K/AKT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.